HUTCHMED reshapes board leadership as veteran independent director plans retirement
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
HUTCHMED (China) ( (HK:0013) ) just unveiled an announcement.
HUTCHMED (China) Limited announced that Professor Mok Shu Kam, Tony will retire from its board at the conclusion of the 12 May 2026 annual general meeting after more than eight years as an independent non-executive director, in line with Hong Kong’s nine-year cap on such roles. He will also step down from his positions as chairman and member of various board committees, with the board emphasizing his key contributions to board composition and the company’s scientific and clinical strategy.
Following his departure, the board plans to appoint Dr Renu Bhatia as Senior and Lead Independent Non-executive Director and chair of the Nomination Committee, while Dr Chaohong Hu will chair the Technical Committee and Professor Tan Shao Weng, Daniel will join the Sustainability Committee. The reshuffle, which is subject to shareholder re-election of the relevant directors, is intended to ensure continuity of independent oversight and governance without any reported disagreements related to the transition.
More about HUTCHMED (China)
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on discovering, developing and commercialising targeted therapies and immunotherapies for cancer and immunological diseases. The company has brought multiple in-house discovered drug candidates to market, with three medicines approved in China and its first product also cleared in the U.S., Europe and Japan, underpinning its global oncology focus.
See more data about 0013 stock on TipRanks’ Stock Analysis page.